Experienced in Hemolytic Anemia
Experienced in Hemolytic Anemia
5275 F Street, 
Sacramento, CA 

Overview

Yung Yim is a Pediatric Hematologist Oncology provider in Sacramento, California. Dr. Yim is rated as an Experienced provider by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Thalassemia, Hereditary Spherocytosis, Beta Thalassemia, Classical Hodgkin Lymphoma, and Bone Marrow Aspiration.

His clinical research consists of participating in 24 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 4 Less Insurance Carriers -

Locations

5275 F Street, Sacramento, CA 95819

Additional Areas of Focus

Dr. Yim has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


24 Clinical Trials

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
View 21 Less Clinical Trials
Similar Doctors
Distinguished in Hemolytic Anemia
Pediatric Pulmonology | Pulmonary Medicine | Pediatrics
Distinguished in Hemolytic Anemia
Pediatric Pulmonology | Pulmonary Medicine | Pediatrics
2521 Stockton Blvd Fl 3, 
Sacramento, CA 
 (1.7 miles away)
Languages Spoken:
English

Shaina Willen is a Pediatric Pulmonologist and a Pulmonary Medicine provider in Sacramento, California. Dr. Willen is rated as an Advanced provider by MediFind in the treatment of Hemolytic Anemia. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Advanced in Hemolytic Anemia
Pediatric Hematology Oncology
Advanced in Hemolytic Anemia
Pediatric Hematology Oncology
7210 Murray Dr, 
Stockton, CA 
 (39.1 miles away)
Languages Spoken:
English

Bindu Sathi is a Pediatric Hematologist Oncology provider in Stockton, California. Dr. Sathi is rated as an Advanced provider by MediFind in the treatment of Hemolytic Anemia. Her top areas of expertise are Hemolytic Anemia, Congenital Hemolytic Anemia, Hemoglobin SC Disease, and Anemia.

Experienced in Hemolytic Anemia
Pediatric Hematology Oncology
Experienced in Hemolytic Anemia
Pediatric Hematology Oncology
1600 Eureka Rd, 
Roseville, CA 
 (15.8 miles away)
Languages Spoken:
English

Amy Cruickshank is a Pediatric Hematologist Oncology provider in Roseville, California. Dr. Cruickshank is rated as an Advanced provider by MediFind in the treatment of Hemolytic Anemia. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Sickle Cell Disease, Alpha Thalassemia, and Febrile Neutropenia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Yim's expertise for a condition
ConditionClose
        View All 14 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile